Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial
Glover S, Sanders AE, Zamora D, Faurot KR, Shaikh SR, Divaris K, Werner K, Trau SP, Bain J, Xie J, Danze S, Singh S, Southern T, Iskander J, Sawicki CM
Nutrients · 0 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- NCATS NIH HHS
- Gobierno
- NIDDK NIH HHS
- Subvenciones
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056350)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-09-11 · Nutrients · vol. 18 · número 18 · pág. 2983
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 0 citas · más que el 73% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Migraine and Headache Studies · Fatty Acid Research and Health · Pain Mechanisms and Treatments
- Palabras clave
- omega-3 polyunsaturated fatty acids, EPA, docosahexaenoic acid, migraine, pediatric migraine, children and adolescents, n-6/n-3 ratio, arachidonic acid, pain intensity, migraine disability, psychological distress, dietary supplementation, inflammation, pain interference
- MeSH
- humans, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, treatment outcome, pilot projects, double-blind method, dietary supplements, adolescent, child, female, male, migraine disorders, patient reported outcome measures
15 autores
- Samantha Glover🇺🇸University of North Carolina at Chapel Hill
- Anne E. Sanders🇺🇸University of North Carolina at Chapel Hill
- Daisy Zamora🇺🇸University of North Carolina at Chapel Hill
- Keturah R. Faurot🇺🇸University of North Carolina at Chapel Hill
- Saame Raza Shaikh🇺🇸University of North Carolina at Chapel Hill
- Kimon Divaris🇺🇸University of North Carolina at Chapel Hill
- Klaus Werner🇺🇸Duke Medical Center
- Steven P. Trau🇺🇸University of North Carolina at Chapel Hill
- Jaclyn Bain🇺🇸University of North Carolina at Chapel Hill
- Jialiu Xie🇺🇸University of North Carolina at Chapel Hill
- Sydney Danze🇺🇸University of North Carolina at Chapel Hill
- Sajan Singh🇺🇸University of North Carolina at Chapel Hill
- Thomas Southern🇺🇸University of North Carolina at Chapel Hill
- Joseph Iskander🇺🇸University of North Carolina at Chapel Hill
- Caroline M. Sawicki🇺🇸 · autor de correspondenciaUniversity of North Carolina at Chapel Hill
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background/objectives
Omega-3 polyunsaturated fatty acids (PUFAs) influence lipid-mediated inflammatory pathways implicated in migraine, yet randomized trial data evaluating biologic effects of omega-3 supplementation in youth with migraine remain limited. This pilot quasi-randomized clinical trial aimed to determine whether 12 weeks of omega-3 PUFA supplementation produces measurable changes in whole-blood EPA and DHA levels in children and adolescents with migraine, and to characterize changes in patient-reported measures of pain, migraine-related disability, and psychological distress.
Methods
We conducted a parallel-group, quasi-randomized, double-blind, placebo-controlled trial in children and adolescents (ages 10-17) with migraine diagnosed per International Classification of Headache Disorders, 3rd edition criteria, recruited from pediatric neurology clinics at two academic medical centers. Of 57 participants allocated 1:1 to daily omega-3 PUFA supplementation (340 mg EPA + 510 mg DHA) or coconut oil placebo for 12 weeks, 44 completed the study and were analyzed. The primary outcome was change in whole-blood omega-3 PUFA index. Secondary outcomes included patient-reported measures of pain intensity, pain interference, migraine-related disability, and psychological distress. Exploratory outcomes included changes in omega-6/omega-3 and arachidonic acid/eicosapentaenoic acid (AA/EPA) ratios. Between-group differences were evaluated using ANCOVA adjusting for baseline values.
Results
Omega-3 supplementation significantly altered lipid biomarker profiles. Compared with placebo, the intervention group demonstrated greater increases in omega-3 PUFA index (adjusted mean difference 1.64; 95% CI 0.94-2.35; p p = 0.003) and AA/EPA ratio (-13.52; 95% CI -21.55 to -5.49; p = 0.002), consistent with the increase in whole-blood omega-3 levels. No significant between-group differences were observed in patient-reported outcomes.
Conclusions
Omega-3 PUFA supplementation significantly altered lipid biomarker profiles in youth with migraine over 12 weeks, supporting a measurable whole-blood EPA + DHA response in this proof-of-concept trial. Future larger-scale trials with longer duration are needed to evaluate clinical effects.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.